Status:
COMPLETED
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
Lead Sponsor:
Allergan
Conditions:
Macular Edema
Retinal Vein Occlusion
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.
Eligibility Criteria
Inclusion
- Diagnosis of macular edema
- Best corrected visual acuity of approximately 20/400 to 20/40 in the study eye
Exclusion
- Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month
- Intraocular surgery, including cataract surgery, and/or laser surgery of any type within 3 months
- Any active ocular infection in either eye
Key Trial Info
Start Date :
July 16 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2015
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT01903720
Start Date
July 16 2013
End Date
March 30 2015
Last Update
April 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul, South Korea